Evidence map›Paper›PMID 35204515›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas.

Wendy Revailler, Anne Ségolène Cottereau, Cedric Rossi, Rudy Noyelle, Thomas Trouillard, Franck Morschhauser, Olivier Casasnovas, Catherine Thieblemont, Steven Le Gouill, Marc André and 4 more

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. International Benchmark for Total Metabolic Tumor Volume Measurement in BaselineJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 2 countries.

Wendy RevaillerCentre de Recherche Clinique de Toulouse, Team 9, 31100 Toulouse, France.
Anne Ségolène CottereauAssistance Publique-Hôpitaux de Paris, Hôpital Cochin, Nuclear Medecine, René Descartes University, 75014 Paris, France.
Cedric RossiCHU Dijon, Hematology, 10 Boulevard Maréchal De Lattre De Tassigny, 21000 Dijon, France.
Rudy NoyelleThales Services, 31400 Toulouse, France.
Thomas TrouillardCentre de Recherche Clinique de Toulouse, Team 9, 31100 Toulouse, France.
Franck MorschhauserULR 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, University of Lille, CHU Lille, 59000 Lille, France.ORCID 0000-0002-3714-9824
Olivier CasasnovasCHU Dijon, Hematology, 10 Boulevard Maréchal De Lattre De Tassigny, 21000 Dijon, France.ORCID 0000-0002-1156-8983
Catherine ThieblemontHemato-Oncology Unit, Saint-Louis University Hospital Center, Public Hospital Network of Paris, 75010 Paris, France.
Steven Le GouillDepartment of Hematology, Nantes University Hospital, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, 44000 Nantes, France.
Marc AndréDepartment of Hematology, Université catholique de Louvain, CHU UcL Namur, 5530 Yvoir, Belgium.
Herve GhesquieresDepartment of Hematology, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre-Bénite, France.
Romain RicciLYSARC, Centre Hospitalier Lyon-Sud, 165 Chemin du Grand Revoyet Bâtiment 2D, 69310 Pierre-Bénite, France.
Michel MeignanLYSA Imaging, Henri Mondor University Hospital, AP-HP, University Paris East, 94000 Créteil, France.
Salim KanounCentre de Recherche Clinique de Toulouse, Team 9, 31100 Toulouse, France.ORCID 0000-0002-8592-3773
Institut Claudius Regaud · FRCHU Dijon Bourgogne · FRAssistance Publique – Hôpitaux de Paris · FRHospices Civils de Lyon · FRInserm · FRThales (France) · FRThe Lymphoma Academic Research Organisation · FRUCLouvain · BEUniversité de Lille · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The total metabolic tumor volume (TMTV) is a new prognostic factor in lymphomas that could benefit from automation with deep learning convolutional neural networks (CNN). Manual TMTV segmentations of 1218 baseline 18FDG-PET/CT have been used for training. A 3D V-NET model has been trained to generate segmentations with soft dice loss. Ground truth segmentation has been generated using a combination of different thresholds (TMTVprob), applied to the manual region of interest (Otsu, relative 41% and SUV 2.5 and 4 cutoffs). In total, 407 and 405 PET/CT were used for test and validation datasets, respectively. The training was completed in 93 h. In comparison with the TMTVprob, mean dice reached 0.84 in the training set, 0.84 in the validation set and 0.76 in the test set. The median dice scores for each TMTV methodology were 0.77, 0.70 and 0.90 for 41%, 2.5 and 4 cutoff, respectively. Differences in the median TMTV between manual and predicted TMTV were 32, 147 and 5 mL. Spearman's correlations between manual and predicted TMTV were 0.92, 0.95 and 0.98. This generic deep learning model to compute TMTV in lymphomas can drastically reduce computation time of TMTV.

Indexed as

convolutional neural networkdeep learninglymphomatotal metabolic tumor volume

Identifiers

PMID35204515
PMCPMC8870809
OpenAlexW4210381648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.